Pfizer Gains Anti-Inflammatory Compound Development Rights Through Incyte Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Under the agreement for CCR2 antagonists, Incyte will maintain rights to multiple sclerosis and a second undisclosed indication.